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Introduction
Thyroid cancer represents a good model for study of angiogenesis and cancer mechanisms as they are vascular and comprise a range of lesions with different degrees of malignancy (1) . Papillary thyroid cancer is the most commonly diagnosed thyroid cancer, accounting for 80% of all cases (1) . The overall prognosis is favourable with 10-year survival rates of over 90%, but in some cases the cancer behaves in an aggressive manner characterized by local recurrence and metastasis (2) . Studies have shown that vascular endothelial growth factor (VEGF) has a pivotal role in the control of angiogenesis and impacts biological aggressiveness in thyroid cancers (3) (4) (5) (6) (7) . However, VEGF is not the only factor involved in angiogenesis in cancer. Endothelins (ETs) are another group of factors that contribute to the control of angiogenesis and growth of cancer.
The endothelins (ETs) are a family of genes which induce DNA synthesis and cellular growth in different tissues, primarily affecting vascular tone and angiogenesis (8) . The endothelin axis is composed of three 21 amino acid proteins, including endothelin-1 (ET-1), endothelin-2 (ET-2), and endothelin-3 (ET-3) paired with two G-protein coupled receptors, endothelin receptor A (ET A R) and endothelin receptor B (ET B R) (9) . In cancer, they have roles in the control of numerous factors in cancer development and progression, including angiogenesis, stromal reaction, epithelial mesenchymal transitions, apoptosis, invasion, metastases and drug resistance (10) .
ET-1 appears to have direct effects on neoplastic cells by inducing cellular proliferation, angiogenesis, migration, invasion and inhibition of apoptosis (10) . ET-1 mediates mitogenic effects in some epithelial tumours such as colorectal, ovarian, and prostate cancers (11) (12) (13) . The ET-1/ ET A R autocrine pathway is crucial in carcinogenesis and metastasis in certain cancers (14) (15) . Increased expression of ET-1 or ET A R has been associated with advanced pathological stages and poorer prognosis in different cancers (16) (17) .
VEGF was shown to be related to ET-1 in angiogenesis. ET-1, through ET A R, upregulates vascular endothelial growth factor (VEGF) which in turn stabilizes the VEGF regulatory protein HIF-1α (18) . Previous studies have demonstrated that ET-1 expression is strongly correlated with neovascularization and VEGF expression via ET A R (19) (20) . In papillary thyroid cancer, the role of endothelins has seldom been studied (21) (22) (23) (24) . In this study, we would like to improve the understanding of angiogenesis in thyroid cancer by investigating the roles of ET-1 and its receptor ET A R in large cohort of patients with papillary thyroid carcinoma.
Materials and Method

Patients and tissue samples
Patients with papillary thyroid carcinomas were recruited from different collaborating hospitals in Australia. The histological sections from these carcinomas and their clinical/pathological data were reviewed by the author (AL). The malignant thyroid tumours were classified with reference to the criteria defined by World Health Organization classification of malignant tumours (25) . The American Joint Committee on Cancer (AJCC)/International Union against Cancer (UICC) tumour-node-metastasis (TNM) staging system was used to stage the thyroid tumours (26) . For each patient selected for the study, one of the paraffin blocks of the primary cancer was chosen. Also, if the patient had lymph node metastases, one block of the lymph node with metastatic cancer was also chosen. The selected archival blocks contained over 90% tumour with < 10% stromal tissue contamination. In addition, blocks from 7 non-cancer thyroid tissues (resected for benign thyroid diseases) were selected as controls In total, 123 papillary thyroid carcinomas from 82 women and 41 men were selected for the study. The age of patients ranged between 18 and 87 years, with an average of 45.5 years. Among the patients, 46% of the patients were < 45 years and 54% of the patients were ≥ 45 years. The carcinomas included 79 conventional papillary thyroid carcinomas, 44 follicular variant of papillary thyroid carcinomas. In 40 patients with papillary thyroid carcinoma, at least one lymph node with metastatic carcinoma was noted and chosen for the study.
RNA extraction
Total RNA was extracted from formalin fixed paraffin embedded tissue samples using Qiagen miRNeasy FFPE Kits (Qiagen Pty. Ltd., Hilden, NRW, Germany). The quality of RNA was assessed using an Experion electrophoresis instrument (Bio-Rad, Hercules, CA, USA). RNA was converted to cDNA using miScript Reverse Transcription kit (Qiagen) according to the manufacturer's instructions. The preparation and evaluation of these samples have been described previously (3).
Real-time polymerase chain reaction (RT-PCR)
Primers were designed for analysis of expression of ET-1 (GenBank accession number NM_001955.4), ET A R (GenBank accession number NM_001957. μl of mRNA at 30ng/μl. In the last tube of each reaction, 6 μl of water was added as nontemplate control. For ET A R study, total volume of 10µl reaction mixture was prepared for PCR as follow: 5µl of iQ SYBR green supermix (Bio-Rad), 1 μl of each 5 μmol/l primer, 2 μl of mRNA at 30ng/μl. In the last tube of each reaction, 2 μl of water was added as nontemplate control.
All samples were run in triplicate and accompanied by a non-template control. The annealing temperature for the primers was 59.5°C. Thermal cycling conditions included initial denaturation for 10 minutes at 95˚C followed by 40 cycles of 30 seconds at 95°C, 15 seconds at 59.5°C and 30 seconds at 72°C. Known concentrations of cDNA from universal human reference RNA (Stratagene, Cedar Creek, TX, USA) were used to build the standard curve for the determination of PCR efficiency. Final products were separated on 1.5% agarose gels to ensure the correct band had been amplified.
The mean values of cycle thresholds (ΔCt) for each triplicate in the PCR were calculated. Expression of ET-1 and ET A R were normalized in each sample using the ΔCt of the target gene and ubiquitous control gene. The fold changes in the target genes were calculated for each sample group using the 2 -ΔΔCt method with the average ΔCt of the normal tissues as the reference point. A fold change of <0.5 was considered as low expression, a fold change of >0.5 and <2 was considered as normal expression, and a fold change of >2 was considered as high expression (19) .
Immunohistochemistry staining for ET-1 and ET A R
A tissue microarray (TMA) was constructed using a Model TMA Galileo CK3500 
Results
Detection of ET axis mRNAs by RT-PCR in primary thyroid carcinomas
The mRNA expression of ET-1 and its receptor (ET A R) in all primary and metastatic papillary thyroid carcinomas as well as in non-cancer thyroid tissue was detected. ET-1 mRNA expression level was elevated in 27% of the primary carcinomas (n=33) compared to the control tissues. The expression was low in 48% (n=39) and normal in 25% (n=31). ET A R mRNA expression was increased in 21% (n=26) of the primary papillary thyroid carcinomas.
The expression was low in 48% (n=59) and normal in 31% (n=38 
Immunohistochemical analysis of ET-1, and ET A R protein expression
ET-1 protein expression was mainly nuclear in thyroid cancers. The adjacent nontumour thyroid often showed weaker nuclear staining. The expression was noted in the primary papillary thyroid carcinomas as well as metastatic thyroid carcinoma in lymph node (Figure 1 ). ET A R protein expression was mainly membranous in papillary thyroid carcinoma.
The adjacent non-tumour thyroid often showed weaker membranous staining. The protein expression was noted in the primary papillary thyroid carcinomas as well as metastatic thyroid carcinoma in lymph node (Figure 2 ).
ET-1 protein expression was tested in 112 of the 123 papillary thyroid carcinomas.
ET-1 protein was expressed at low levels in 6% (n=7) of the papillary thyroid carcinomas whereas a high expression level was seen in 94% (n=105). Of the 31 cases with high expression of ET-1 mRNA, 29 (94%) revealed a high level of ET-1 protein.
ET A R protein expression was studied in 74 of the 123 papillary thyroid carcinomas.
ET A R was expressed at high level in 95% (n=70) and at low level in 5% (n=4) of the carcinomas. All the 18 cases with high expression of ET A R mRNA showed high expression of ET A R.
There was no significant difference between ET-1 and ET A R protein expression levels in papillary thyroid carcinomas with lymph node metastases, those without lymph node metastases and metastatic carcinomas in the lymph nodes. Also, no correlation of the ET-1/ ET A R immunohistochemical stain with clinicopathological features was demonstrated. There was a significant difference between ET A R expression level and cancer size, as larger cancers expressed higher levels of ET A R. This would make sense in terms of increased sensitivity to angiogenic signals for larger cancers with higher oxygen demands, and although the difference was not significant, our data also shows a trend of increased ET-1 expression in larger tumours. It has been shown that ET A R overexpression is associated with aggressive cancer behaviour and a worse prognosis in ovarian cancer (27) . Indeed in our study, we also found increased expression of ET-1 in metastatic thyroid cancer. Therefore, it can be hypothesized that ET (34) . Differences in ET-1 and ET A R immunostaining in these and our studies indicate that ET axis expression levels are different in various cancer types, and may depend on the propensity of the originating cell type to utilise certain vascular triggers, rather than being an intrinsic response of the vasculature to cancer.
Discussion
In papillary thyroid carcinoma, ET-1 production and antagonism of ET A R have been demonstrated in human thyroid cancer cells lines (22). ET-1 or ET
In conclusion, elevated ET-1/ ET A R expression levels seen in our research were produced by primary thyroid cancers or metastases compared to primary cancers, and may also be produced by endothelial cells within highly vascularized primary tumours and metastases. These results suggest that ET axis expression could be used as a possible indicator to predict the aggression levels of papillary thyroid carcinomas, identifying which carcinomas have metastasised as well as helping to locate the presence of new and developing metastases in lymph nodes and other locations, due to the role of the axis in establishing tumour vasculature. Although we have identified a link between ET axis expression and cancer aggression, more research is needed to determine whether ET axis levels in thyroid cancer tissues could serve as prognostic markers, or an indicator of response to therapy.
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Table2. The correlation between ET A R mRNA expression and clinicopathological characteristics of 123 papillary thyroid carcinomas
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